Pomerantz LLP Has Filed Class Action Against AeroVironment, Inc. – AVAV

AeroVironment (AVAV) is facing a securities class action alleging violations of Sections 10(b) and 20(a) / Rule 10b-5 tied to the SCAR program for BADGER phased array antennas. During the period referenced, the stock dropped sharply on negative program updates—down 15.77% to $330.89/share after a Jan. 20, 2026 stop-work order, then down another 17.42% to $208.32/share on March 2, 2026 news of the Space Force reopening/reassessing SCAR, and down 6.24% to $207.73/share after Q3 FY2026 results including a $151.3 million goodwill impairment and an operating loss of $179.0 million. The lawsuit claims AeroVironment allegedly overstated prospects while allegedly understating imminent competition and disclosure issues related to the program.

Analysis

The litigation headline is noise relative to the real impairment: the market is being forced to re-rate AVAV from a perceived sole-source growth story to a multi-vendor procurement story with lower visibility and weaker pricing power. That matters more than the legal timetable because a defense customer moving from bespoke to COTS/multi-award typically compresses the implied terminal margin and the revenue multiple at the same time.

The second-order winner set is broader than the article implies. Any supplier with modular space-comms or phased-array capability and lower-cost manufacturing can now compete for slice-of-program awards; that favors larger incumbents with balance-sheet capacity and integration breadth over “one-contract” story stocks. It also raises the bar for every defense-tech name trading on a single program narrative, because investors will now assign higher breakage risk to stop-work, re-bid, and scope-reduction events across the sector.

The near-term reaction is mostly litigation-driven and can mean-revert, but the 1-3 month catalyst path is the SCAR acquisition strategy and whether AVAV can replace lost scope with disclosed backlog. Over 6-18 months, the key variable is whether the BlueHalo purchase was an accretive platform acquisition or a value trap that gets followed by more goodwill pressure. The thesis is falsified if management shows durable replacement revenue, restored scope, or a materially better win rate on the new procurement structure.

Key Decisions for Investors

• Short AVAV on any 5-10% relief rally over the next 2-4 weeks; the catalyst is structural re-rating, not the lawsuit itself. Risk/reward favors downside continuation unless the stock reclaims the post-breakdown area and management quantifies replacement work.
• Use AVAV puts or a bearish call spread into the next 30-60 days if borrow is tight; prefer defined risk because headline-driven squeezes are possible. Cover if AVAV closes back above the prior breakdown zone and the company updates guidance upward.
• Pair: long XAR or ITA versus short AVAV for a sector-neutral expression of idiosyncratic procurement risk. This isolates the thesis that the issue is company-specific re-bid exposure rather than a broad defense demand slowdown.